ALLUVI: A IN-DEPTH INVESTIGATION INTO THE MEDICATION'S PROSPECTS

Alluvi, formerly BI 4744, offers a significant development in obesity care. This dual activator targeting both glucagon-like peptide-1 and GIP targets demonstrates compelling results in clinical studies, arguably surpassing available GLP-1 target stimulators. Early information suggest substantial